HighVista Strategies LLC Has $1.81 Million Position in Liquidia Co. (NASDAQ:LQDA)

HighVista Strategies LLC raised its stake in Liquidia Co. (NASDAQ:LQDA) by 48.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 180,947 shares of the company’s stock after purchasing an additional 59,193 shares during the period. HighVista Strategies LLC owned 0.24% of Liquidia worth $1,809,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Charles Schwab Investment Management Inc. increased its position in Liquidia by 144.8% during the third quarter. Charles Schwab Investment Management Inc. now owns 390,257 shares of the company’s stock worth $3,903,000 after acquiring an additional 230,820 shares during the period. Sapient Capital LLC bought a new position in Liquidia during the third quarter worth about $1,336,000. BNP Paribas Financial Markets increased its position in Liquidia by 735.1% during the third quarter. BNP Paribas Financial Markets now owns 140,190 shares of the company’s stock worth $1,402,000 after acquiring an additional 123,402 shares during the period. Acuta Capital Partners LLC bought a new position in Liquidia during the third quarter worth about $735,000. Finally, Boston Partners bought a new position in Liquidia during the first quarter worth about $762,000. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Liquidia Stock Performance

LQDA opened at $11.23 on Tuesday. The company’s 50 day moving average is $10.76 and its 200-day moving average is $11.34. Liquidia Co. has a 1-year low of $6.83 and a 1-year high of $16.99.

Insider Activity

In other news, General Counsel Russell Schundler sold 2,576 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $28,619.36. Following the sale, the general counsel now directly owns 486,048 shares in the company, valued at approximately $5,399,993.28. This trade represents a 0.53 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Roger Jeffs sold 8,053 shares of the firm’s stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total transaction of $89,468.83. Following the completion of the sale, the chief executive officer now owns 812,193 shares in the company, valued at approximately $9,023,464.23. The trade was a 0.98 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 19,307 shares of company stock worth $214,703. Corporate insiders own 30.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on LQDA shares. Lifesci Capital started coverage on shares of Liquidia in a research report on Thursday, October 3rd. They set an “outperform” rating and a $30.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and set a $29.00 price target on shares of Liquidia in a research report on Thursday, November 14th. Raymond James raised shares of Liquidia from an “outperform” rating to a “strong-buy” rating in a report on Monday, August 19th. BTIG Research decreased their target price on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating on the stock in a report on Monday, August 19th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of Liquidia in a report on Thursday, November 14th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).